

CLAIMS

1. A crystal form of 6-((1R,2S)-2-aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridine-3(2H)-one citrate, characterized by an X-ray powder diffraction (XRPD) pattern using Cu K α radiation comprising peaks at 2 θ angles of 9.4, 16.6, 17.4, 18.9, and 19.2° $\pm$ 0.2 degrees.
2. The crystal form of claim 1, characterized by an XRPD pattern using Cu K α radiation comprising peaks at 2 θ angles of 9.4, 16.6, 17.4, 18.9, 19.2, and 20.7° $\pm$ 0.2 degrees.
3. The crystal form of claim 1, characterized by an XRPD pattern using Cu K α radiation comprising peaks at 2 θ angles of 4.7, 9.4, 16.6, 17.4, 18.9, 19.2, 20.7, and 23.0° $\pm$ 0.2 degrees.
4. The crystal form of claim 1, characterized by an XRPD pattern using Cu K α radiation comprising peaks at 2 θ angles of 4.7, 9.4, 13.0, 13.8, 14.1, 16.6, 17.4, 18.4, 18.9, 19.2, 20.7, 23.0, 23.3, 23.6, and 25.0° $\pm$ 0.2 degrees.
5. The crystal form of any one of claims 1 to 4, wherein the crystal form is not hygroscopic.
6. A pharmaceutical composition comprising the crystal form of any one of claims 1 to 5 and one or more pharmaceutically acceptable carriers.
7. The pharmaceutical composition of claim 6, which is suitable for oral administration.
8. The pharmaceutical composition of claim 7, which is a dosage form selected from a capsule and a tablet.
9. The pharmaceutical composition of claim 7, wherein the dosage form is a tablet.
10. A crystal form of any one of claims 1 to 5 for use in the treatment of a cancer in a subject.

11. A pharmaceutical composition of any one of claims 6 to 9 for use in the treatment of a cancer in a subject.
12. The crystal form for use of claim 10, wherein the cancer is a leukemia or lymphoma.
13. The crystal form for use of claim 10, wherein the cancer is selected from indolent non-Hodgkin's lymphoma (iNHL), peripheral T-cell lymphoma (PTCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), nasopharyngeal carcinoma, gastric carcinoma, breast cancer, ovarian cancer, lung cancer and a post-transplant lymphoproliferative disorder (PT-LPD).
14. The crystal form for use of claim 10, wherein the cancer is selected from indolent non-Hodgkin's lymphoma (iNHL), mantle cell lymphoma, post-transplant lymphoproliferative disorder (PT-LPD), diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML).
15. The crystal form for use of claim 10, wherein the cancer is selected from diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia (AML).
16. The pharmaceutical composition for use of claim 11, wherein the cancer is a leukemia or lymphoma.
17. The pharmaceutical composition for use of claim 11, wherein the cancer is selected from indolent non-Hodgkin's lymphoma (iNHL), peripheral T-cell lymphoma (PTCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), nasopharyngeal carcinoma, gastric carcinoma, breast cancer, ovarian cancer, lung cancer and a post-transplant lymphoproliferative disorder (PT-LPD).
18. The pharmaceutical composition for use of claim 11, wherein the cancer is selected from indolent non-Hodgkin's lymphoma (iNHL), mantle cell lymphoma, post-transplant

lymphoproliferative disorder (PT-LPD), diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML).

19. The pharmaceutical composition for use of claim 11, wherein the cancer is selected from diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia (AML).